Myovant announced that the company’s Phase III HERO trial relugolix met the study’s primary endpoint and six key secondary endpoints in advanced prostate cancer.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2019-11-19 12:22:352019-11-19 12:59:41Myovant's Prostate Cancer Drug Ready for FDA Filing
